ContraVir Pharmaceuticals Announces $9.0 Million Private Placement
Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on $9.0 Million Private Placement
New York, October 28, 2014 (Global Newswire) – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that it has represented ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, on a $9 million private placement consisting of Series A Convertible Preferred stock to a non-U.S investor.
Pursuant to the private placement, the Series A Preferred Stock can be converted into shares of common stock at the conversion price of $0.48 per share. The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.
- Sichenzia Ross Ference LLP Represents ThinkEquity LLC in $17.25 Million Initial Public Offering of Common Stock of Forza X1, Inc. - August 17, 2022
- Sichenzia Ross Ference LLP Joins Splash Beverage Group, Inc. in Ringing Opening Bell at NYSE - July 29, 2022
- Sichenzia Ross Ference LLP Represents Roth Capital Partners in Public Offering of Common Stock of Crown Electrokinetics Corp. - July 26, 2022